Arpeggio Bio logo

Arpeggio BioArpeggio Bio develops drugs targeting transcription factors using AI…

Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.

2019-05-02
Active
Early
S19
20
Healthcare
United States of AmericaAmerica / Canada
Arpeggio Bio screenshot
More About Arpeggio Bio

Arpeggio Bio: Network Biology Meets Drug Discovery

Introduction

Arpeggio Bio engineers medicine based on the biological network as a whole, not just a single target. Our innovative approach leverages the world's fastest platform for transcriptomic sequencing to map chemistry to network biology.

Key Features

  • World's fastest platform for transcriptomic sequencing
  • Extensive chemotranscriptome database with over 250k entries
  • Measurement of over 2.3 billion mRNAs
  • Active drug programs targeting chronic diseases

Use Cases

  • Tackling drug resistance in cancer
  • Addressing chronic kidney disease
  • Developing treatments for neurodegeneration

Pricing

Pricing details are customized based on the specific needs and scale of the project. Contact us for a tailored quote.

Teams

Arpeggio Bio's team comprises experts in pharmaceutical and therapeutics industries, including our Chief Business Officer, Kevin Eastwood, who brings over 25 years of experience. Our collaborative team is dedicated to advancing the field of network biology and drug discovery.

Explore our technology and pipeline to learn more about how Arpeggio Bio is revolutionizing medicine.